Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
<i>Background and Objectives</i>: One of the most frequently mutated oncogenes in cancer belongs to the Ras family of proto-oncogenes, which encode distinct key signaling events. RAS gain-of-function mutations are present in ~30% of all human cancers, with KRAS being the most frequently...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/10/1039 |
| _version_ | 1797513979487059968 |
|---|---|
| author | Veronica Aran Mariano Zalis Tatiane Montella Carlos Augusto Moreira de Sousa Bruno L. Ferrari Carlos Gil Ferreira |
| author_facet | Veronica Aran Mariano Zalis Tatiane Montella Carlos Augusto Moreira de Sousa Bruno L. Ferrari Carlos Gil Ferreira |
| author_sort | Veronica Aran |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: One of the most frequently mutated oncogenes in cancer belongs to the Ras family of proto-oncogenes, which encode distinct key signaling events. RAS gain-of-function mutations are present in ~30% of all human cancers, with KRAS being the most frequently mutated isoform showing alterations in different cancer types including lung cancer. This study aimed to investigate the incidence of KRAS mutations, and concomitant mutations, in advanced non-small cell lung adenocarcinoma patients. <i>Materials and Methods</i>: This was a retrospective study, where genomic DNA extracted from paraffin-embedded tumor tissues from 121 Brazilian advanced non-small cell lung adenocarcinoma patients were analyzed to evaluate via Next Generation Sequencing (NGS) the incidence of KRAS mutations and co-occurring mutations and correlate, when possible, to clinicopathological characteristics. Statistical analyses were performed to calculate the prevalence of mutations and to investigate the association between mutational status, mutation type, and sex. <i>Results</i>: The results showed a prevalence of male (N = 63; 54.8%) compared to female patients (N = 52, 45.2%), and mutant KRAS was present in 20.86% (24/115) of all samples. Interestingly, 33.3% of the mutant KRAS samples showed other mutations simultaneously. <i>Conclusions</i>: This study revealed the presence of rare KRAS concomitant mutations in advanced lung adenocarcinoma patients. Further investigation on the importance of these genomic alterations in patient prognosis and treatment response is warranted. |
| first_indexed | 2024-03-10T06:25:10Z |
| format | Article |
| id | doaj.art-a7c06c40a033421eb0e7b9e04597eaba |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T06:25:10Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-a7c06c40a033421eb0e7b9e04597eaba2023-11-22T19:03:52ZengMDPI AGMedicina1010-660X1648-91442021-09-015710103910.3390/medicina57101039Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma PatientsVeronica Aran0Mariano Zalis1Tatiane Montella2Carlos Augusto Moreira de Sousa3Bruno L. Ferrari4Carlos Gil Ferreira5Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro 20231-092, BrazilOncoclínicas, São Paulo 22251-060, BrazilOncoclínicas, Rio de Janeiro 22251-060, BrazilDepartamento de Tecnologias da Informação e Educação em Saúde (DTIES), da Faculdade de Ciências Médicas (FCM), na Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro 20550-170, BrazilOncoclínicas, São Paulo 22251-060, BrazilOncoclínicas, Rio de Janeiro 22251-060, Brazil<i>Background and Objectives</i>: One of the most frequently mutated oncogenes in cancer belongs to the Ras family of proto-oncogenes, which encode distinct key signaling events. RAS gain-of-function mutations are present in ~30% of all human cancers, with KRAS being the most frequently mutated isoform showing alterations in different cancer types including lung cancer. This study aimed to investigate the incidence of KRAS mutations, and concomitant mutations, in advanced non-small cell lung adenocarcinoma patients. <i>Materials and Methods</i>: This was a retrospective study, where genomic DNA extracted from paraffin-embedded tumor tissues from 121 Brazilian advanced non-small cell lung adenocarcinoma patients were analyzed to evaluate via Next Generation Sequencing (NGS) the incidence of KRAS mutations and co-occurring mutations and correlate, when possible, to clinicopathological characteristics. Statistical analyses were performed to calculate the prevalence of mutations and to investigate the association between mutational status, mutation type, and sex. <i>Results</i>: The results showed a prevalence of male (N = 63; 54.8%) compared to female patients (N = 52, 45.2%), and mutant KRAS was present in 20.86% (24/115) of all samples. Interestingly, 33.3% of the mutant KRAS samples showed other mutations simultaneously. <i>Conclusions</i>: This study revealed the presence of rare KRAS concomitant mutations in advanced lung adenocarcinoma patients. Further investigation on the importance of these genomic alterations in patient prognosis and treatment response is warranted.https://www.mdpi.com/1648-9144/57/10/1039KRASadvanced lung adenocarcinomaconcomitant mutationsNGS |
| spellingShingle | Veronica Aran Mariano Zalis Tatiane Montella Carlos Augusto Moreira de Sousa Bruno L. Ferrari Carlos Gil Ferreira Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients Medicina KRAS advanced lung adenocarcinoma concomitant mutations NGS |
| title | Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients |
| title_full | Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients |
| title_fullStr | Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients |
| title_full_unstemmed | Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients |
| title_short | Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients |
| title_sort | evaluation of kras concomitant mutations in advanced lung adenocarcinoma patients |
| topic | KRAS advanced lung adenocarcinoma concomitant mutations NGS |
| url | https://www.mdpi.com/1648-9144/57/10/1039 |
| work_keys_str_mv | AT veronicaaran evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients AT marianozalis evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients AT tatianemontella evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients AT carlosaugustomoreiradesousa evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients AT brunolferrari evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients AT carlosgilferreira evaluationofkrasconcomitantmutationsinadvancedlungadenocarcinomapatients |